GSK buoyed by hopes of defending asthma drug – Financial Times


Daily Mail

GSK buoyed by hopes of defending asthma drug
Financial Times
GSK jumped 2.8 per cent to £12.62 on hopes it will be able to defend Advair, its blockbuster asthma franchise, from competition
FTSE 100 ends busy week on a positive note, despite opening dip on Wall StreetThe Guardian
Glaxo breathes easier as threat to Advair recedesReuters

all 17 news articles »

View full post on asthma – Google News

Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug – International Business Times

Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug
International Business Times
Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually,
Lotus Pharmaceuticals Receives SFDA Approval to Initiate Phase I Clinical PR Newswire (press release)

all 12 news articles »

View full post on asthma – Google News